Tick Borne Encephalitis Market Report 2026

The tick borne encephalitis market size has grown strongly in recent years. It will grow from $10.53 billion in 2025 to $11.34 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to expansion of tick habitats due to climate change, rising incidence of vector-borne infections, availability of tbe vaccines in endemic regions, growth of public health awareness campaigns, expansion of diagnostic testing capabilities.

The tick borne encephalitis market size is expected to see strong growth in the next few years. It will grow to $15.09 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing investments in vaccine research and development, rising demand for travel-related immunization, expansion of early diagnostic screening programs, growing adoption of integrated disease monitoring platforms, increasing focus on infectious disease prevention. Major trends in the forecast period include increasing adoption of preventive vaccination programs, rising demand for rapid diagnostic testing, growing awareness of tick-borne diseases, expansion of integrated disease surveillance systems, enhanced focus on public health preparedness.

The increasing climate change is anticipated to drive the growth of the tick-borne encephalitis market in the coming years. Climate change refers to long-term alterations in global temperatures and weather patterns, mainly caused by human activities such as burning fossil fuels and deforestation. The rise in climate change results from excessive fossil fuel consumption, which releases significant amounts of greenhouse gases like carbon dioxide and methane into the atmosphere, trapping heat and raising global temperatures. Climate change stimulates demand for tick-borne encephalitis treatment by enlarging the habitats of disease-carrying ticks due to higher temperatures and milder winters, leading to increased infection rates and greater need for diagnostics, vaccines, and antiviral therapies. For example, in November 2024, according to the World Meteorological Organization (WMO), a Switzerland-based specialized agency of the United Nations, from January to September 2024, the global mean surface air temperature was 1.54°C above the pre-industrial average (±0.13°C margin of uncertainty), driven by a warming El Niño event. Therefore, the increasing climate change is fostering the growth of the tick-borne encephalitis market.

The rise in international travel is expected to boost the growth of the tick-borne encephalitis market in the coming years. International travel refers to the movement of people across national borders for purposes such as tourism, business, education, or migration. The increase in international travel is attributed to rising disposable incomes, allowing more individuals to afford leisure trips, business visits, and educational opportunities abroad. International travel drives demand for tick-borne encephalitis treatment as more travelers visit endemic areas, increasing their exposure to infected ticks and creating a higher need for preventive vaccinations and post-exposure medical care. For instance, in January 2025, according to the United Nations World Tourism Organization, a Spain-based specialized agency of the United Nations, around 1.4 billion tourists traveled internationally in 2024, nearly fully recovering to pre-pandemic levels (99%). This represents an 11% increase from 2023, with 140 million additional international arrivals. Therefore, the growing international travel is contributing to the growth of the tick-borne encephalitis market.

The increase in government funding for healthcare services is expected to support the growth of the tick-borne encephalitis market in the coming years. Government funding refers to financial assistance provided to organizations, projects, or individuals to promote public services, economic development, research, or other policy goals. The growth in government funding is driven by rising investments in public health and infrastructure, as governments allocate more resources to strengthen healthcare systems, support economic recovery, and advance research and development initiatives. Government funding benefits tick-borne encephalitis management by supporting vaccination programs, enabling broader immunization coverage in endemic regions, reducing infection rates, and improving public access to preventive healthcare. For example, in May 2024, according to a report by the Office for National Statistics, a UK-based government agency, UK government expenditure was the main source of healthcare financing in 2023, totaling $309 billion (£239 billion) and accounting for 81.9% of total healthcare spending. Therefore, the increasing government funding for healthcare services is driving the growth of the tick-borne encephalitis market.

Major companies operating in the tick borne encephalitis market are Pfizer Inc., Sanofi Pasteur, Novartis AG, GlaxoSmithKline (GSK) Plc, Bavarian Nordic, Valneva SE, Microgen, DIESSE Diagnostica Senese S.p.A., QED Bioscience Inc., Serion Immunologics, Chumakov Federal Scientific Center, Merck & Co. Inc., AstraZeneca Plc, Johnson & Johnson (Janssen Pharmaceuticals), CSL Limited, Takeda Pharmaceutical Company Limited, Serum Institute of India Pvt Ltd, BioNTech SE, Zydus Cadila, Bharat Biotech International Limited, Walvax Biotechnology Co Ltd.

Europe was the largest region in the tick borne encephalitis market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the tick borne encephalitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tick borne encephalitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the tick-borne encephalitis market by increasing costs of imported vaccines, diagnostic reagents, laboratory equipment, antiviral drugs, and cold-chain logistics systems. European regions with high disease prevalence are most affected due to dependence on cross-border vaccine supply chains, while Asia-Pacific faces cost pressures in diagnostic kit sourcing. These tariffs are impacting vaccination program budgets and procurement timelines. However, they are also encouraging regional vaccine manufacturing, local diagnostic production, and strengthened public health supply chains to support long-term disease control efforts.

The tick borne encephalitis market research report is one of a series of new reports that provides tick borne encephalitis market statistics, including tick borne encephalitis industry global market size, regional shares, competitors with a tick borne encephalitis market share, detailed tick borne encephalitis market segments, market trends and opportunities, and any further data you may need to thrive in the tick borne encephalitis industry. This tick borne encephalitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tick-borne encephalitis (TBE) is a viral infection transmitted to humans through the bite of an infected tick, mainly of the Ixodes species. The virus targets the central nervous system, causing brain inflammation (encephalitis). Symptoms can range from mild flu-like signs to severe neurological complications, including fever, headache, confusion, and in some cases, paralysis or seizures.

The main products for tick-borne encephalitis include TBE vaccines, tick repellents, diagnostic tests, and antiviral drugs. TBE vaccines are biological preparations designed to stimulate the immune system to recognize and fight the TBE virus. The disease is caused by various virus types, including European TBE virus, Siberian TBE virus, and Far Eastern TBE virus, and vaccines can be administered via parenteral and other routes. These products are distributed through both online and offline channels and are used by travelers, outdoor enthusiasts, healthcare providers, and research institutions.

The tick-borne encephalitis market consists of sales of immune globulins, protective clothing and tick barriers, and surveillance and monitoring systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.